EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Bridging Radiation Rapidly and Effectively Cytoreduces High-Risk Relapsed/Refractory Aggressive B Cell Lymphomas Prior to Chimeric Antigen Receptor T Cell Therapy

Harper Hubbeling, Emily A Silverman, Laure Michaud, Ana Alarcon Tomas, Roni Shouval, Jessica Flynn, Sean Devlin, N Ari Wijetunga, Kathryn R Tringale, Connie Batlevi, Parastoo Dahi, Sergio Giralt und 12 weitere

Transplantation and Cellular Therapy · 2023-04 · 29 (4) · 259.e1-259.e10

DOI: 10.1016/j.jtct.2022.12.021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplantation and Cellular Therapy, 2023-04. Verfasst von Harper Hubbeling und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute, Connecticut Bar Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Greater tumor burden before CD19-targeted chimeric antigen receptor T cell (CAR-T) therapy predicts lower complete response rate and shorter overall survival (OS) in patients with aggressive non-Hodgkin lymphoma (NHL). Recent patterns of failure studies have identified lesion characteristics, including size, standard uptake value (SUV), and extranodal location, as associated with post-CAR-T therapy failure. Here we analyzed the effect of bridging radiation-containing treatment (BRT) on pre-CAR-T therapy lesion- and patient-level characteristics and post-CAR-T therapy outcomes, including patterns of failure. Consecutive NHL patients who received radiation therapy from 30 days before leukapheresis until CAR T cell infusion were reviewed. Metabolic tumor volume (MTV) was contoured with a threshold SUV of 4. The first post-CAR-T therapy failures were categorized as preexisting/new/mixed with respect to pre-CAR-T therapy disease and in-field/marginal/distant with respect to BRT. Forty-one patients with diffuse large B cell lymphoma (DLBCL; n = 33), mantle cell lymphoma (n = 7), or Burkitt lymphoma (n = 1) were identified. BRT significantly improved established high-risk parameters of post-CAR-T therapy progression, including in-field median MTV (45.5 cc to .2 cc; P < .001), maximum SUV (18.1 to 4.4; P < .001), diameter (5.5 cm to 3.2 cm; P < .001), and lactate dehydrogenase (LDH; 312 to 232; P = .025). DLBCL patients with lower LDH levels post-BRT had improved progression-free survival (PFS; P = .001). In DLBCL, first failures were new in 7 of 19 patients, preexisting in 5 of 19, and mixed in 7 of 19; with respect to BRT, 4 of 19 were in-field and 4 of 19 were marginal. Post-CAR-T therapy survival was similar in patients with initially low MTV and those with newly low MTV post-BRT using a statistically determined threshold of 16 cc (PFS, 26 months versus 31 months; OS unreached for both). BRT produced significant cytoreductions in diameter, SUV, MTV, and LDH, all predictors of poor post-CAR-T therapy outcomes. Similar PFS and OS in patients with initially low MTV and those who achieved newly low MTV after BRT suggest that BRT may "convert" poor-risk patients to better risk. In the future, the response to BRT may allow for risk stratification and individualization of bridging strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenLymphoma, Non-HodgkinLymphoma, Large B-Cell, DiffuseHumansAdultImmunotherapy, AdoptiveCell- and Tissue-Based Therapy

Stichwörter der Autor:innen

BridgingChimeric antigen receptor T cellDiffuse large B cell lymphomaLymphomaRadiation

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Department of Radiology, Molecular Imaging, and Therapy Service, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Department of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: Imberb@mskcc.org.

Förderung

  • NCI NIH HHS
  • National Cancer Institute
  • Connecticut Bar Foundation
  • Leukemia & Lymphoma Society

Zitieren

APA

Hubbeling, H., Silverman, E. A., Michaud, L., Tomas, A. A., Shouval, R., Flynn, J., Devlin, S., Wijetunga, N. A., Tringale, K. R., Batlevi, C., Dahi, P., Giralt, S., Lin, R., Park, J., Scordo, M., Sauter, C., Shah, G., Hajj, C., Salles, G., …, & Imber, B. S. (2023). Bridging Radiation Rapidly and Effectively Cytoreduces High-Risk Relapsed/Refractory Aggressive B Cell Lymphomas Prior to Chimeric Antigen Receptor T Cell Therapy. Transplantation and Cellular Therapy, 29(4), 259.e1-259.e10. https://doi.org/10.1016/j.jtct.2022.12.021

Vancouver

Hubbeling H, Silverman EA, Michaud L, Tomas AA, Shouval R, Flynn J, et al. Bridging Radiation Rapidly and Effectively Cytoreduces High-Risk Relapsed/Refractory Aggressive B Cell Lymphomas Prior to Chimeric Antigen Receptor T Cell Therapy. Transplantation and Cellular Therapy. 2023;29(4):259.e1-259.e10. doi:10.1016/j.jtct.2022.12.021

BibTeX
@article{Hubbeling2023,
  author = {Hubbeling, Harper and Silverman, Emily A and Michaud, Laure and Tomas, Ana Alarcon and Shouval, Roni and Flynn, Jessica and Devlin, Sean and Wijetunga, N Ari and Tringale, Kathryn R and Batlevi, Connie and Dahi, Parastoo and Giralt, Sergio and Lin, Richard and Park, Jae and Scordo, Michael and Sauter, Craig and Shah, Gunjan and Hajj, Carla and Salles, Gilles and Schoder, Heiko and Palomba, M Lia and Perales, Miguel-Angel and Yahalom, Joachim and Imber, Brandon S},
  title = {Bridging Radiation Rapidly and Effectively Cytoreduces High-Risk Relapsed/Refractory Aggressive B Cell Lymphomas Prior to Chimeric Antigen Receptor T Cell Therapy},
  journal = {Transplantation and Cellular Therapy},
  year = {2023},
  volume = {29},
  number = {4},
  pages = {259.e1--259.e10},
  doi = {10.1016/j.jtct.2022.12.021}
}
Kostenlos starten →